Intravenous amantadine improves levadopa-induced dyskinesias: An acute double-blind placebo-controlled study

Movement Disorders

Volumn 16, Issue 3, 2001, Pages 515-520

  Del Dotto, Paolo ^a   Pavese, Nicola ^a   Gambaccini, Gianna ^a   Bernardini, Silvia ^a   Metman, Leonard Verhagen ^b   Chase, Thomas N ^b   Bonuccelli, Ubaldo ^a  

^a UNIVERSITY OF PISA   (Italy)

^b NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

Author keywords

Amantadine; Dyskinesia; Levodopa; Parkinson's disease

Indexed keywords

AMANTADINE; ANTIPARKINSON AGENT; DOPA DECARBOXYLASE INHIBITOR; GLUTAMATE RECEPTOR ANTAGONIST; LEVODOPA; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; PERGOLIDE; PLACEBO; SELEGILINE;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG MECHANISM; DYSKINESIA; FEMALE; HUMAN; MALE; MOTOR DYSFUNCTION; MOTOR PERFORMANCE; PARKINSON DISEASE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; RECEPTOR BLOCKING;

AGED; AMANTADINE; ANTIPARKINSON AGENTS; DOPAMINE AGENTS; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; DYSKINESIA, DRUG-INDUCED; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; LEVODOPA; MALE; MIDDLE AGED; PARKINSON DISEASE; RECEPTORS, N-METHYL-D-ASPARTATE; REMISSION INDUCTION;

EID: 0035353741     PISSN: 08853185     EISSN: None     Source Type: Journal    
DOI: 10.1002/mds.1112     Document Type: Article

References (28)

1. Obeso J, Rodriguez-Oroz MC, Rodriguez M, DeLong MR, Olanow CW. Pathophysiology of levodopa-induced dyskinesias in Parkinson's disease: problems with the current model. Ann Neurol 2000;47(Suppl 1):S22-S34.
2. Brotchie JM. Adjuncts to dopamine replacement: a pragmatic approach to reducing the problem of dyskinesia in Parkinson's disease. Mov Disord 1998;13:871-876.
3. Carpentier AF, Bonnet AM, Vidailhet M, Agid Y. Improvement of L-dopa-induced dyskinesia by propanolol in Parkinson's disease. Neurology 1996; 46:1548-1551.
4. Durif F, Vidailhet M, Bonnet AM, Blin J, Agid Y. L-dopa-induced dyskinesias are improved by fluoxetine. Neurology 1995;45:1855-1858.
5. Rascol A, Fabre N, Blin R, Poulik J, Sabatini U, Senard JM, Are M, Montastruc JL, Rascol A. Naltrexone, an opiate antagonist, fails to modify motor symptoms in patients with Parkinson's disease. Mov Disord 1994;4:437-440.
6. Verhagen Metman L, Del Dotto P, Blanchet PJ, van den Munckhof P, Chase TN. Blockade of glutamatergic transmission as treatment for dyskinesias and motor fluctuations in Parkinson's disease. Amino acids 1998;14:75-82.
7. Engber TM, Papa SM, Boldry RC, Chase TN. NMDA receptor blockade reverses motor response alterations induced by L-dopa. NeuroReport 1994;5:2586-2588.
8. Papa SM, Chase TN. L-dopa induced dyskinesias improved by a glutamate antagonist in parkinsonian monkeys. Ann Neurol 1996; 39:574-578.
9. Rajput AH, Rajput A, Lang AE, Kumar R, Uitti RJ, Galvez-Jimenez N. New use for an old drug: amantadine benefits L-dopa-induced dyskinesias. Mov Disord 1998;13:851-854.
10. Verhagen Metman L, Del Dotto P, van den Munckhof P, Fang J, Mouradian MM, Chase TN. Amantadine as treatment for dyskinesias and motor fluctuations in Parkinson's disease. Neurology 1998;5:1323-1326.
11. Snow BJ, Macdonald L, Mcauley D, Wallis W. The effect of amantadine on levodopa-induced dyskinesias in Parkinson's disease: a double-blind, placebo-controlled study. Clin Neuropharmacol 2000;23:82-85.
12. Kornhuber J, Bormann J, Hubers M; Rusche K, Riederer P. Effects of 1-aminoadamantanes at the MK-801-binding site of the NMDA-receptor-gated ion channel: a human postmortem brain study. Eur J Pharmacol 1991;206:297-300.
13. Haoki FY, Sitar DS. Clinical pharmacokinetics of amantadine hydrochloride. Clin Pharmacokin 1988;14:35-51.
14. Fleiss JL. The measurement of interrater agreement. In: Fleiss JL, ed. Statistical methods for rates and proportions. New York: John Wiley & Sons; 1981:212-236.
15. Blanchet PJ, Konitsiotis S, Chase TN. Amantadine reduces L-dopa induced dyskinesias in parkinsonian monkeys. Mov Disord 1998; 5:798-802.
16. Northoff J, Eckert J, Fritze J. Glutamatergic dysfunction in catatonia? Successful treatment of three acute akinetic catatonic patients with the NMDA antagonist amantadine. J Neurol Neurosurg Psychiatry 1997;62:404-406.
17. Von Voigtlander PF, Moore KE. Dopamine: release from the brain in vivo by amantadine. Science 1971;174:408-410.
18. Bailey EV, Stone TW. The mechanism of action of amantadine in parkinsonism: a review. Arch Int Pharmacodyn Ther 1975;216: 246-262.
19. Li XM, Juorio AV, Qi J, Boulton AA. Amantadine increase aromatic L-amino acid decarboxylase mRNA in PC12 cells. J Neurosci Res 1998;53:490-493.
20. Nastuk WL, Su P, Doubilet P. Anticholinergic and membrane activities of amantadine and memantine in neuromuscular transmission. Nature 1976;264:76-79.
21. Hauser RA, Olanow CW. Orobuccal dyskinesia, associated with trihexyphenidyl therapy in a patient with Parkinson's disease. Mov Disord 1993;8:512-514.
22. Kornhuber J, Quack G, Danysz W, Jellinger K, Danielczyk W, Gsell W, Riederer P. Therapeutic brain concentration of the NMDA receptor antagonist amantadine. Neuropharmacology 1995;34:713-721.
23. Chase TN, Engber TM, Mouradian MM. Contribution of dopaminergic and glutamatergic mechanisms to the pathogenesis of motor response complications in Parkinson's disease. Adv Neurol 1996; 69:497-501.
24. Dunah AW, Wang Y, Yasuda RP, Kameyama K, Huganir RL, Wolfe BB, Standaert DG. Alteration in subunit expression, composition, and phosphorylation of striatal N-methyl-D-aspartate glutamate receptors in a rat 6-hydroxydopamine model of Parkinson's disease. Mol Pharmacol 2000;57:342-352.
25. Ciliax BJ, Greenamyre JT, Levey AI. Functional biochemistry and molecular neuropharmacology of the basal ganglia and motor systems. In: Watts RL, Koller WC, eds. Movement disorders. Neurological principles and practice. New York: MacGraw Hill; 1997: 99-116.
26. Oh JD, Vaughan CL, Chase TN. Effect of dopamine denervation and dopamine agonist administration on serine phosphorylation of striatal NMDA receptor subunits. Brain Res 1999;821:433-442.
27. Verhagen Metman L, Del Dotto P, Nattè R, van der Munckhof P, Chase TN. Dextromethorphan improves L-dopa-induced dyskinesias in Parkinson's disease. Neurology 1998;51:203-206.
28. Merello M, Nouzeilles MI, Cammarota A, Leiguarda R. Effect of memantine (NMDA antagonist) on Parkinson's disease: a double-blind crossover randomized study. Clin Neuropharmacol 1999;22: 273-276.